|
|||||
|
|
Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer |
|
| Authors: | Yassine Lalami MD Camillo Garcia MD Patrick Flamen MD PhD Lieveke Ameye Marianne Paesmans Ahmad Awada MD PhD |
| Affiliation: | 1. Department of Medical Oncology, Institut Jules Bordet, Université de Bruxelles, Brussels, Belgium;2. Department of Nuclear Medicine, Institut Jules Bordet, Université de Bruxelles, Brussels, Belgium;3. Data Center, Institut Jules Bordet, Université de Bruxelles, Brussels, Belgium |
| Abstract: | |
| Keywords: | sorafenib fluorodeoxyglucose (FDG) positron emission tomography (PET) head and neck cancer antiangiogenic drugs |